3fc2 › Citations

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR
Clin Cancer Res 15 3094-102 (2009)
Cited: 231 times
EuropePMC logo PMID: 19383823

Abstract

Results

BI 6727 is a highly potent (enzyme IC(50) = 0.87 nmol/L, EC(50) = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties. First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high volume of distribution and a long terminal half-life in mice (V(ss) = 7.6 L/kg, t(1/2) = 46 h) and rats (V(ss) = 22 L/kg, t(1/2) = 54 h). Second, BI 6727 has physicochemical and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules. Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer. With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.

Reviews - 3fc2 mentioned but not cited (4)

  1. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Lee KS, Burke TR, Park JE, Bang JK, Lee E. Trends Pharmacol Sci 36 858-877 (2015)
  2. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Kumar S, Kim J. Biomed Res Int 2015 705745 (2015)
  3. Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. Park JE, Hymel D, Burke TR, Lee KS. F1000Res 6 1024 (2017)
  4. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Molecules 26 7069 (2021)

Articles - 3fc2 mentioned but not cited (5)

  1. Why Some Targets Benefit from beyond Rule of Five Drugs. Egbert M, Whitty A, Keserű GM, Vajda S. J Med Chem 62 10005-10025 (2019)
  2. Design and Synthesis of Aminopyrimidinyl Pyrazole Analogs as PLK1 Inhibitors Using Hybrid 3D-QSAR and Molecular Docking. Bhujbal SP, Kim H, Bae H, Hah JM. Pharmaceuticals (Basel) 15 1170 (2022)
  3. A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells. Patel JR, Thangavelu P, Terrell RM, Israel B, Sarkar AB, Davidson AM, Zhang K, Khupse R, Tilghman SL. Biomolecules 12 531 (2022)
  4. Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies. El-Kalyoubi S, El-Sebaey SA, Elfeky SM, Al-Ghulikah HA, El-Zoghbi MS. Pharmaceuticals (Basel) 16 1303 (2023)
  5. QSAR, molecular docking, design, and pharmacokinetic analysis of 2-(4-fluorophenyl) imidazol-5-ones as anti-breast cancer drug compounds against MCF-7 cell line. Lawal HA, Uzairu A, Uba S. J Bioenerg Biomembr 52 475-494 (2020)


Reviews citing this publication (59)

  1. Cell cycle proteins as promising targets in cancer therapy. Otto T, Sicinski P. Nat Rev Cancer 17 93-115 (2017)
  2. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Strebhardt K. Nat Rev Drug Discov 9 643-660 (2010)
  3. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Gutteridge RE, Ndiaye MA, Liu X, Ahmad N. Mol Cancer Ther 15 1427-1435 (2016)
  4. PLK1, A Potential Target for Cancer Therapy. Liu Z, Sun Q, Wang X. Transl Oncol 10 22-32 (2017)
  5. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Gjertsen BT, Schöffski P. Leukemia 29 11-19 (2015)
  6. Targeted therapies for non-small cell lung cancer. Dempke WC, Suto T, Reck M. Lung Cancer 67 257-274 (2010)
  7. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Liu X. Transl Oncol 8 185-195 (2015)
  8. Understanding the Polo Kinase machine. Archambault V, Lépine G, Kachaner D. Oncogene 34 4799-4807 (2015)
  9. The σ2 receptor: a novel protein for the imaging and treatment of cancer. Mach RH, Zeng C, Hawkins WG. J Med Chem 56 7137-7160 (2013)
  10. Emerging therapeutic targets in bladder cancer. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Cancer Treat Rev 41 170-178 (2015)
  11. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Chopra P, Sethi G, Dastidar SG, Ray A. Expert Opin Investig Drugs 19 27-43 (2010)
  12. PLK1 as an oncology target: current status and future potential. McInnes C, Wyatt MD. Drug Discov Today 16 619-625 (2011)
  13. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Pharmacol Ther 142 258-269 (2014)
  14. The role of Plk3 in oncogenesis. Helmke C, Becker S, Strebhardt K. Oncogene 35 135-147 (2016)
  15. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ. Br J Pharmacol 166 858-876 (2012)
  16. Selecting initial treatment of acute myeloid leukaemia in older adults. Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Blood Rev 31 43-62 (2017)
  17. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Van den Bossche J, Lardon F, Deschoolmeester V, De Pauw I, Vermorken JB, Specenier P, Pauwels P, Peeters M, Wouters A. Med Res Rev 36 749-786 (2016)
  18. Novel drugs for older patients with acute myeloid leukemia. Montalban-Bravo G, Garcia-Manero G. Leukemia 29 760-769 (2015)
  19. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, Bang JK. Mol Cells 32 209-220 (2011)
  20. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis. Fu Z, Wen D. Cancers (Basel) 9 E131 (2017)
  21. PLK4: a promising target for cancer therapy. Zhao Y, Wang X, Wang X. J Cancer Res Clin Oncol 145 2413-2422 (2019)
  22. Mitosis as an anti-cancer drug target. Salmela AL, Kallio MJ. Chromosoma 122 431-449 (2013)
  23. Current assessment of polo-like kinases as anti-tumor drug targets. Craig SN, Wyatt MD, McInnes C. Expert Opin Drug Discov 9 773-789 (2014)
  24. Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Louwen F, Yuan J. Oncotarget 4 958-971 (2013)
  25. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Erba HP. Leuk Res 39 183-191 (2015)
  26. Polo-like kinases and acute leukemia. Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C. Oncogene 38 1-16 (2019)
  27. Plk1-targeted therapies in TP53- or RAS-mutated cancer. Yim H, Erikson RL. Mutat Res Rev Mutat Res 761 31-39 (2014)
  28. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Zhang X, Wei C, Liang H, Han L. Front Oncol 11 587554 (2021)
  29. Targeting polo-like kinase 1 in acute myeloid leukemia. Brandwein JM. Ther Adv Hematol 6 80-87 (2015)
  30. Vimentin and cytokeratin: Good alone, bad together. Kuburich NA, den Hollander P, Pietz JT, Mani SA. Semin Cancer Biol 86 816-826 (2022)
  31. Polo-like kinase inhibitors in hematologic malignancies. Talati C, Griffiths EA, Wetzler M, Wang ES. Crit Rev Oncol Hematol 98 200-210 (2016)
  32. Mitotic Poisons in Research and Medicine. Škubník J, Jurášek M, Ruml T, Rimpelová S. Molecules 25 E4632 (2020)
  33. Modulating polo-like kinase 1 as a means for cancer chemoprevention. Schmit TL, Ledesma MC, Ahmad N. Pharm Res 27 989-998 (2010)
  34. Second-Generation Antimitotics in Cancer Clinical Trials. Novais P, Silva PMA, Amorim I, Bousbaa H. Pharmaceutics 13 1011 (2021)
  35. Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F. Front Oncol 12 903016 (2022)
  36. Therapeutic Targeting of DNA Damage Response in Cancer. Choi W, Lee ES. Int J Mol Sci 23 1701 (2022)
  37. Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives. Diogo V, Teixeira J, Silva PM, Bousbaa H. Clin Colorectal Cancer 16 1-8 (2017)
  38. Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Janning M, Fiedler W. Future Oncol 10 1157-1165 (2014)
  39. Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens. Hashemi P, Sadowski I. Med Res Rev 40 881-908 (2020)
  40. Natural products as new antimitotic compounds for anticancer drug development. Paier CRK, Maranhão SS, Carneiro TR, Lima LM, Rocha DD, Santos RDS, Farias KM, Moraes-Filho MO, Pessoa C. Clinics (Sao Paulo) 73 e813s (2018)
  41. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1. Berg A, Berg T. Chembiochem 17 650-656 (2016)
  42. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Christoph DC, Schuler M. Expert Rev Anticancer Ther 11 1115-1130 (2011)
  43. Therapeutic potential of pteridine derivatives: A comprehensive review. Carmona-Martínez V, Ruiz-Alcaraz AJ, Vera M, Guirado A, Martínez-Esparza M, García-Peñarrubia P. Med Res Rev 39 461-516 (2019)
  44. The role of aurora A and polo-like kinases in high-risk lymphomas. Murga-Zamalloa C, Inamdar KV, Wilcox RA. Blood Adv 3 1778-1787 (2019)
  45. Volasertib for AML: clinical use and patient consideration. Hao Z, Kota V. Onco Targets Ther 8 1761-1771 (2015)
  46. Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Front Oncol 5 193 (2015)
  47. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE. Int J Mol Sci 20 E667 (2019)
  48. Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Wissing MD, van Diest PJ, van der Wall E, Gelderblom H. Expert Opin Investig Drugs 22 635-661 (2013)
  49. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. Grieselhuber NR, Mims AS. Curr Hematol Malig Rep 16 192-206 (2021)
  50. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cui L, Liu Y, Pang Y, Qian T, Quan L, Cheng Z, Dai Y, Ye X, Pang Y, Shi J, Ke X, Wu D, Fu L. Cancer Gene Ther 27 1-14 (2020)
  51. Novel molecular targets in hepatocellular carcinoma. Chow AK, Yau SW, Ng L. World J Clin Oncol 11 589-605 (2020)
  52. CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes. Roth A, Gihring A, Bischof J, Pan L, Oswald F, Knippschild U. Cancers (Basel) 14 1345 (2022)
  53. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Bailey FP, Clarke K, Kalirai H, Kenyani J, Shahidipour H, Falciani F, Coulson JM, Sacco JJ, Coupland SE, Eyers PA. Pigment Cell Melanoma Res 31 253-266 (2018)
  54. Targeted therapy of acute myeloid leukemia. Carneiro BA, Altman JK, Kaplan JB, Ossenkoppele G, Swords R, Platanias LC, Giles FJ. Expert Rev Anticancer Ther 15 399-413 (2015)
  55. Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells. Majera D, Mistrik M. Int J Mol Sci 21 E9431 (2020)
  56. Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Ferrari S, Gentili C. Front Genet 7 128 (2016)
  57. Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. Bao R, Chan P. J Exp Pharmacol 3 21-34 (2011)
  58. Putting a bit into the polo-box domain of polo-like kinase 1. Park JE, Kim TS, Meng L, Bang JK, Kim BY, Lee KS. J Anal Sci Technol 6 27 (2015)
  59. A new wave of innovations within the DNA damage response. Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. Signal Transduct Target Ther 8 338 (2023)

Articles citing this publication (163)

  1. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Nat Chem Biol 10 305-312 (2014)
  2. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Blood 124 1426-1433 (2014)
  3. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G. Eur J Cancer 48 179-186 (2012)
  4. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA. Cancer 120 976-982 (2014)
  5. Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling. Wu J, Ivanov AI, Fisher PB, Fu Z. Elife 5 e10734 (2016)
  6. Polo-like kinase 1 as target for cancer therapy. Weiß L, Efferth T. Exp Hematol Oncol 1 38 (2012)
  7. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC. Br J Cancer 110 2434-2440 (2014)
  8. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin LA, Marangoni E. Nat Commun 11 4053 (2020)
  9. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R. BMC Cancer 12 80 (2012)
  10. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, Tontsch-Grunt U, Wernitznig A, Savarese F, Hofmann MH, Albrecht C, Geiselmann L, Reschke M, Garin-Chesa P, Zuber J, Moll J, Adolf GR, Kraut N. J Pharmacol Exp Ther 352 579-589 (2015)
  11. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G. Curr Oncol 19 e28-35 (2012)
  12. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, De Maria R, Zeuner A. Stem Cells 30 1819-1830 (2012)
  13. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer 61 158-164 (2014)
  14. MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Chakravarthi BV, Goswami MT, Pathi SS, Robinson AD, Cieślik M, Chandrashekar DS, Agarwal S, Siddiqui J, Daignault S, Carskadon SL, Jing X, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S. Oncogene 35 6330-6340 (2016)
  15. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S. J Invest Dermatol 135 2475-2483 (2015)
  16. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F. J Clin Oncol 34 706-713 (2016)
  17. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Hatzimichael E, Georgiou G, Benetatos L, Briasoulis E. Am J Blood Res 3 29-51 (2013)
  18. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cao YY, Yu J, Liu TT, Yang KX, Yang LY, Chen Q, Shi F, Hao JJ, Cai Y, Wang MR, Lu WH, Zhang Y. Cell Death Dis 9 17 (2018)
  19. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Cancer Res 75 405-414 (2015)
  20. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. Raab M, Krämer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dötsch C, Bug G, Ottmann O, Becker S, Pachl F, Kuster B, Strebhardt K. Mol Oncol 9 140-154 (2015)
  21. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. Clin Lung Cancer 16 457-465 (2015)
  22. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AM, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D, U KP, Harvey KJ, Ferretti P, Paddison PJ, Preston JE, Abbott NJ, Bertone P, Smith A, Pollard SM. PLoS One 8 e77053 (2013)
  23. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Hugle M, Belz K, Fulda S. Cell Death Differ 22 1946-1956 (2015)
  24. Polo-like Kinase 1 Regulates Vimentin Phosphorylation at Ser-56 and Contraction in Smooth Muscle. Li J, Wang R, Gannon OJ, Rezey AC, Jiang S, Gerlach BD, Liao G, Tang DD. J Biol Chem 291 23693-23703 (2016)
  25. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A. Neoplasia 14 410-419 (2012)
  26. Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis. de Cárcer G, Wachowicz P, Martínez-Martínez S, Oller J, Méndez-Barbero N, Escobar B, González-Loyola A, Takaki T, El Bakkali A, Cámara JA, Jiménez-Borreguero LJ, Bustelo XR, Cañamero M, Mulero F, de Los Ángeles Sevilla M, Montero MJ, Redondo JM, Malumbres M. Nat Med 23 964-974 (2017)
  27. Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. Long T, Neitz RJ, Beasley R, Kalyanaraman C, Suzuki BM, Jacobson MP, Dissous C, McKerrow JH, Drewry DH, Zuercher WJ, Singh R, Caffrey CR. PLoS Negl Trop Dis 10 e0004356 (2016)
  28. Cell death signaling and anticancer therapy. Galluzzi L, Vitale I, Vacchelli E, Kroemer G. Front Oncol 1 5 (2011)
  29. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Clin Cancer Res 22 1674-1686 (2016)
  30. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Raab M, Sanhaji M, Matthess Y, Hörlin A, Lorenz I, Dötsch C, Habbe N, Waidmann O, Kurunci-Csacsko E, Firestein R, Becker S, Strebhardt K. Nat Commun 9 1106 (2018)
  31. Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD. Jang MS, Lee SJ, Kim CJ, Lee CW, Kim E. Oncogene 30 471-481 (2011)
  32. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Hepatology 58 1362-1374 (2013)
  33. Letter Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. Burkard ME, Santamaria A, Jallepalli PV. ACS Chem Biol 7 978-981 (2012)
  34. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Kreis NN, Louwen F, Zimmer B, Yuan J. Oncotarget 6 6611-6626 (2015)
  35. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H. Br J Haematol 163 214-222 (2013)
  36. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Kobayashi Y, Yamauchi T, Kiyoi H, Sakura T, Hata T, Ando K, Watabe A, Harada A, Taube T, Miyazaki Y, Naoe T. Cancer Sci 106 1590-1595 (2015)
  37. Requirement for PLK1 kinase activity in the maintenance of a robust spindle assembly checkpoint. O'Connor A, Maffini S, Rainey MD, Kaczmarczyk A, Gaboriau D, Musacchio A, Santocanale C. Biol Open 5 11-19 (2015)
  38. Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines. Driscoll DL, Chakravarty A, Bowman D, Shinde V, Lasky K, Shi J, Vos T, Stringer B, Amidon B, D'Amore N, Hyer ML. PLoS One 9 e111060 (2014)
  39. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Sanhaji M, Louwen F, Zimmer B, Kreis NN, Roth S, Yuan J. Cell Cycle 12 1340-1351 (2013)
  40. Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1. Schubert A, Koziol U, Cailliau K, Cailliau K, Vanderstraete M, Dissous C, Brehm K. PLoS Negl Trop Dis 8 e2870 (2014)
  41. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. de Braud F, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D, Sikken P, De Pas T. Ann Oncol 26 2341-2346 (2015)
  42. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA. Lung Cancer 104 126-130 (2017)
  43. GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors. Thorne CA, Wichaidit C, Coster AD, Posner BA, Wu LF, Altschuler SJ. Nat Chem Biol 11 58-63 (2015)
  44. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kachhap SK. FASEB J 27 4279-4293 (2013)
  45. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCK. J Med Chem 60 4805-4817 (2017)
  46. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R. BMC Cancer 16 647 (2016)
  47. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells. Cholewa BD, Pellitteri-Hahn MC, Scarlett CO, Ahmad N. J Proteome Res 13 5041-5050 (2014)
  48. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N. Cancer Lett 385 179-187 (2017)
  49. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Li J, Hong MJ, Chow JP, Man WY, Mak JP, Ma HT, Poon RY. Oncotarget 6 9327-9340 (2015)
  50. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Hartsink-Segers SA, Exalto C, Allen M, Williamson D, Clifford SC, Horstmann M, Caron HN, Pieters R, Den Boer ML. Haematologica 98 1539-1546 (2013)
  51. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S. Clin Cancer Res 19 404-414 (2013)
  52. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A. Leuk Lymphoma 54 708-713 (2013)
  53. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Li H, Wang H, Sun Z, Guo Q, Shi H, Jia Y. Biosci Rep 37 BSR20170852 (2017)
  54. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. Gohda J, Suzuki K, Liu K, Xie X, Takeuchi H, Inoue JI, Kawaguchi Y, Ishida T. Sci Rep 8 3521 (2018)
  55. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Neoplasia 21 363-375 (2019)
  56. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. Awada A, Dumez H, Aftimos PG, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P. Invest New Drugs 33 611-620 (2015)
  57. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer. Xin X, Lin F, Wang Q, Yin L, Mahato RI. ACS Appl Mater Interfaces 11 14647-14659 (2019)
  58. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Clin Cancer Res 17 7194-7203 (2011)
  59. Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics. Noack S, Raab M, Matthess Y, Sanhaji M, Krämer A, Győrffy B, Kaderali L, El-Balat A, Becker S, Strebhardt K. Oncotarget 9 25842-25859 (2018)
  60. A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. Gemble S, Buhagiar-Labarchède G, Onclercq-Delic R, Biard D, Lambert S, Amor-Guéret M. J Cell Sci 129 3167-3177 (2016)
  61. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau G. Blood Adv 3 552-563 (2019)
  62. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H. Mol Cancer Ther 17 2551-2563 (2018)
  63. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells. Reid RJ, Du X, Sunjevaric I, Rayannavar V, Dittmar J, Bryant E, Maurer M, Rothstein R. Genetics 204 807-819 (2016)
  64. Exploration of CTCF post-translation modifications uncovers Serine-224 phosphorylation by PLK1 at pericentric regions during the G2/M transition. Del Rosario BC, Kriz AJ, Del Rosario AM, Anselmo A, Fry CJ, White FM, Sadreyev RI, Lee JT. Elife 8 e42341 (2019)
  65. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Shan HM, Shi Y, Quan J. ChemMedChem 10 158-163 (2015)
  66. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK. Invest New Drugs 36 85-95 (2018)
  67. Letter Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H. Br J Haematol 184 1018-1021 (2019)
  68. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Abdelfatah S, Berg A, Huang Q, Yang LJ, Hamdoun S, Klinger A, Greten HJ, Fleischer E, Berg T, Wong VKW, Efferth T. Acta Pharm Sin B 9 1021-1034 (2019)
  69. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A. Cancer Lett 439 56-65 (2018)
  70. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. Archambault V, Normandin K. Cell Cycle 16 1220-1224 (2017)
  71. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells. Zhang Z, Zhang G, Kong C. J Cell Mol Med 21 758-767 (2017)
  72. Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Zheng DW, Xue YQ, Li Y, Di JM, Qiu JG, Zhang WJ, Jiang QW, Yang Y, Chen Y, Wei MN, Huang JR, Wang K, Wei X, Shi Z. Am J Cancer Res 6 2476-2488 (2016)
  73. Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer. Xie FF, Pan SS, Ou RY, Zheng ZZ, Huang XX, Jian MT, Qiu JG, Zhang WJ, Jiang QW, Yang Y, Li WF, Shi Z, Yan XJ. Am J Cancer Res 5 3548-3559 (2015)
  74. YM155 inhibits topoisomerase function. Hong M, Ren MQ, Silva J, Paul A, Wilson WD, Schroeder C, Weinberger P, Janik J, Hao Z. Anticancer Drugs 28 142-152 (2017)
  75. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. Bogado RF, Pezuk JA, de Oliveira HF, Tone LG, Brassesco MS. Anticancer Drugs 26 56-63 (2015)
  76. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T. Invest New Drugs 34 66-74 (2016)
  77. In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. Mol Cancer Ther 18 1637-1648 (2019)
  78. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. Li L, Xue W, Shen Z, Liu J, Hu M, Cheng Z, Wang Y, Chen Y, Chang H, Liu Y, Liu B, Zhao J. Mol Ther Oncolytics 18 215-225 (2020)
  79. A phase I study of volasertib combined with afatinib, in advanced solid tumors. Machiels JP, Peeters M, Herremans C, Surmont V, Specenier P, De Smet M, Pilz K, Strelkowa N, Liu D, Rottey S. Cancer Chemother Pharmacol 76 843-851 (2015)
  80. An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Spaniol K, Boos J, Lanvers-Kaminsky C. Anticancer Drugs 22 531-542 (2011)
  81. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Chen Y, Zhang J, Li D, Jiang J, Wang Y, Si S. Oncotarget 8 1234-1246 (2017)
  82. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. EMBO Mol Med 11 e9960 (2019)
  83. Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Czaplinski S, Hugle M, Stiehl V, Fulda S. Oncotarget 7 8700-8711 (2016)
  84. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Krause M, Kummer B, Deparade A, Eicheler W, Pfitzmann D, Yaromina A, Kunz-Schughart LA, Baumann M. Radiother Oncol 108 422-428 (2013)
  85. Volasertib preclinical activity in high-risk hepatoblastoma. Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, Svalina MN, Settelmeyer T, Matlock K, Lathara M, Mussini C, Geller JI, Noakes C, Sloma I, Bharathy N, Cairo S, Keller C. Oncotarget 10 6403-6417 (2019)
  86. Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Adachi Y, Ishikawa Y, Kiyoi H. Oncotarget 8 78452-78465 (2017)
  87. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells. Ritter A, Friemel A, Kreis NN, Louwen F, Yuan J. Oncotarget 7 84271-84285 (2016)
  88. Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice. Lee JS, Lee Y, André EA, Lee KJ, Nguyen T, Feng Y, Jia N, Harris BT, Burns MP, Pak DTS. PLoS One 14 e0219691 (2019)
  89. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Mol Oncol 13 1196-1213 (2019)
  90. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R. Oncotarget 8 97290-97303 (2017)
  91. The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF. Oncotarget 9 10497-10509 (2018)
  92. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Münch C, Dragoi D, Frey AV, Thurig K, Lübbert M, Wäsch R, Bogatyreva L, Hauschke D, Lassmann S, Werner M, May AM. Leuk Res 39 462-470 (2015)
  93. A Versatile Cell Death Screening Assay Using Dye-Stained Cells and Multivariate Image Analysis. Collins TJ, Ylanko J, Geng F, Andrews DW. Assay Drug Dev Technol 13 547-557 (2015)
  94. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Normandin K, Lavallée JF, Futter M, Beautrait A, Duchaine J, Guiral S, Marinier A, Archambault V. Sci Rep 5 37581 (2016)
  95. Increased Expression of Phosphorylated Polo-Like Kinase 1 and Histone in Bypass Vein Graft and Coronary Arteries following Angioplasty. Sur S, Swier VJ, Radwan MM, Agrawal DK. PLoS One 11 e0147937 (2016)
  96. Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1. Aspinall CF, Zheleva D, Tighe A, Taylor SS. Oncotarget 6 36472-36488 (2015)
  97. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. Yang Z, Liang SQ, Saliakoura M, Yang H, Vassella E, Konstantinidou G, Tschan M, Hegedüs B, Zhao L, Gao Y, Xu D, Deng H, Marti TM, Kocher GJ, Wang W, Schmid RA, Peng RW. EMBO Mol Med 13 e13193 (2021)
  98. Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck. de Boer DV, Martens-de Kemp SR, Buijze M, Stigter-van Walsum M, Bloemena E, Dietrich R, Leemans CR, van Beusechem VW, Braakhuis BJM, Brakenhoff RH. Oncotarget 8 97928-97940 (2017)
  99. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Hemasphere 5 e617 (2021)
  100. Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells. Lanceta L, O'Neill C, Lypova N, Li X, Rouchka E, Waigel S, Gomez-Gutierrez JG, Chesney J, Imbert-Fernandez Y. Genes (Basel) 11 E467 (2020)
  101. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma. Liu TT, Yang KX, Yu J, Cao YY, Ren JS, Hao JJ, Pan BQ, Ma S, Yang LY, Cai Y, Wang MR, Zhang Y. J Mol Med (Berl) 96 807-817 (2018)
  102. Distinct surfaces on Cdc5/PLK Polo-box domain orchestrate combinatorial substrate recognition during cell division. Almawi AW, Langlois-Lemay L, Boulton S, Rodríguez González J, Melacini G, D'Amours D, Guarné A. Sci Rep 10 3379 (2020)
  103. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P. Clin Exp Ophthalmol 45 288-296 (2017)
  104. Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers. Stratmann JA, Sebastian M. Lung Cancer (Auckl) 10 67-80 (2019)
  105. Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer. Pathak A, Tanwar S, Kumar V, Banarjee BD. Vivechan Int J Res 9 36-49 (2018)
  106. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain. Park JE, Kim TS, Kim BY, Lee KS. Cell Cycle 14 3624-3634 (2015)
  107. Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib. Hong M, Ren M, Silva J, Kennedy T, Choi J, Cowell JK, Hao Z. Am J Cancer Res 4 135-147 (2014)
  108. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Lin SF, Lin JD, Yeh CN, Huang YT, Chou TC, Wong RJ. Endocr Relat Cancer 26 727-738 (2019)
  109. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA. Mol Cancer Ther 18 1615-1627 (2019)
  110. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells. Sydor S, Jafoui S, Wingerter L, Swoboda S, Mertens JC, Gerken G, Canbay A, Paul A, Fingas CD. World J Gastroenterol 23 4007-4015 (2017)
  111. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Fu G, Somasundaram RT, Jessa F, Srivastava G, MacMillan C, Witterick I, Walfish PG, Ralhan R. Oncotarget 7 17162-17181 (2016)
  112. Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. WeiΔ LM, Hugle M, Fulda S. Oncotarget 8 52445-52456 (2017)
  113. Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene arrangements and potential molecular targeted therapies. Kikuchi H, Higuchi T, Hashida Y, Taniguchi A, Kamioka M, Taguchi T, Yokoyama A, Murakami I, Fujieda M, Daibata M. Oncotarget 9 33482-33499 (2018)
  114. Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells. Shi Z, An N, Lu BM, Zhou N, Yang SL, Zhang B, Li CY, Wang ZJ, Wang F, Wu CF, Bao JK. Cell Prolif 47 219-230 (2014)
  115. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Rödel F, Martin D, Helmke C, Balermpas P, Fokas E, Wieland U, Rave-Fränk M, Kitz J, Matthess Y, Raab M, Strebhardt K, Rödel C. Oncotarget 7 53339-53349 (2016)
  116. Research Support, Non-U.S. Gov't Polo-like kinases in AML. Berg T, Bug G, Ottmann OG, Strebhardt K. Expert Opin Investig Drugs 21 1069-1074 (2012)
  117. Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. P Solans B, Fleury A, Freiwald M, Fritsch H, Haug K, Trocóniz IF. Clin Pharmacokinet 57 379-392 (2018)
  118. A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening. Abdelfatah S, Berg A, Böckers M, Efferth T. J Adv Res 16 145-156 (2019)
  119. Aneugen Molecular Mechanism Assay: Proof-of-Concept With 27 Reference Chemicals. Bernacki DT, Bryce SM, Bemis JC, Dertinger SD. Toxicol Sci 170 382-393 (2019)
  120. Application of design of experiments (DoE) optimization to the one-pot synthesis of 4,6-dihydropteridinones. Stone S, Wang T, Liang J, Cochran J, Green J, Gu W. Org Biomol Chem 13 10471-10476 (2015)
  121. Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma. Pandey A, Tripathi SC, Mai J, Hanash SM, Shen H, Mitra S, Rostomily RC. Cancers (Basel) 13 5114 (2021)
  122. Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirements. Symeonidou V, Jakobczyk H, Bashanfer S, Malouf C, Fotopoulou F, Kotecha RS, Anderson RA, Finch AJ, Ottersbach K. Cell Rep 37 109900 (2021)
  123. Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models. Gunasekaran P, Yim MS, Ahn M, Soung NK, Park JE, Kim J, Bang G, Shin SC, Choi J, Kim M, Kim HN, Lee YH, Chung YH, Lee K, EunKyeong Kim E, Jeon YH, Kim MJ, Lee KR, Kim BY, Lee KS, Ryu EK, Bang JK. J Med Chem 63 14905-14920 (2020)
  124. Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma. Higuchi T, Hashida Y, Taniguchi A, Kamioka M, Daibata M. Sci Rep 7 11026 (2017)
  125. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1. Yun T, Qin T, Liu Y, Lai L. ChemMedChem 11 713-717 (2016)
  126. Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells. Nonomiya Y, Noguchi K, Tanaka N, Kasagaki T, Katayama K, Sugimoto Y. Cancer Sci 107 1877-1887 (2016)
  127. Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study. Foong CS, Sandanaraj E, Brooks HB, Campbell RM, Ang BT, Chong YK, Tang C. J Biomol Screen 17 1136-1150 (2012)
  128. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition. Chen JL, Chen JP, Huang YS, Tsai YC, Tsai MH, Jaw FS, Cheng JC, Kuo SH, Shieh MJ. Strahlenther Onkol 192 260-268 (2016)
  129. Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression. Jeon MY, Min KJ, Woo SM, Seo SU, Kim S, Park JW, Kwon TK. Int J Mol Sci 18 E2568 (2017)
  130. A cell based, high throughput assay for quantitative analysis of Hedgehog pathway activation using a Smoothened activation sensor. Albert EA, Bökel C. Sci Rep 7 14341 (2017)
  131. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors. Chen DX, Huang J, Liu M, Xu YG, Jiang C. Arch Pharm (Weinheim) 348 2-9 (2015)
  132. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. Li P, Shi Y, Gao D, Xu H, Zou Y, Wang Z, Li W. Int J Biol Sci 18 6145-6162 (2022)
  133. Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1. Alverez CN, Park JE, Toti KS, Xia Y, Krausz KW, Rai G, Bang JK, Gonzalez FJ, Jacobson KA, Lee KS. J Med Chem 63 14087-14117 (2020)
  134. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Abdelfatah S, Fleischer E, Klinger A, Wong VKW, Efferth T. Invest New Drugs 38 1-9 (2020)
  135. PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production. Srinivas US, Tay NSC, Jaynes P, Anbuselvan A, Ramachandran GK, Wardyn JD, Hoppe MM, Hoang PM, Peng Y, Lim S, Lee MY, Peethala PC, An O, Shendre A, Tan BWQ, Jemimah S, Lakshmanan M, Hu L, Jakhar R, Sachaphibulkij K, Lim LHK, Pervaiz S, Crasta K, Yang H, Tan P, Liang C, Ho L, Khanchandani V, Kappei D, Yong WP, Tan DSP, Bordi M, Campello S, Tam WL, Frezza C, Jeyasekharan AD. Oncogene 41 1986-2002 (2022)
  136. QSAR models for thiophene and imidazopyridine derivatives inhibitors of the Polo-Like Kinase 1. Comelli NC, Duchowicz PR, Castro EA. Eur J Pharm Sci 62 171-179 (2014)
  137. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Van den Bossche J, Domen A, Peeters M, Deben C, De Pauw I, Jacobs J, De Bruycker S, Specenier P, Pauwels P, Vermorken JB, Lardon F, Wouters A. Cancers (Basel) 11 E1893 (2019)
  138. Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. Goroshchuk O, Vidarsdottir L, Björklund AC, Hamil AS, Kolosenko I, Dowdy SF, Palm-Apergi C. Sci Rep 10 2688 (2020)
  139. Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer. Noor A, Umelo IA, Kronenberger P, Giron P, De Vlieghere E, De Wever O, Teugels E, De Grève J. Oncotarget 9 28731-28744 (2018)
  140. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer. Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Clin Cancer Res 29 1557-1568 (2023)
  141. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest. Chen F, Zhuo X, Qin T, Guo X, Zhang C, Lai L. Chem Biol Drug Des 89 732-740 (2017)
  142. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors. Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A. Bioorg Med Chem Lett 22 7615-7622 (2012)
  143. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Sahin K, Tuzcu M, Yabas M, Orhan C, Sahin N, Ozercan IH. Invest New Drugs 36 388-395 (2018)
  144. Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. Guo J, Chaney KE, Choi K, Witek G, Patel AV, Xie H, Lin D, Whig K, Xiong Y, Schultz DC, Ratner N, Field J. Am J Cancer Res 10 856-869 (2020)
  145. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer. Lin SF, Yeh CN, Huang YT, Chou TC, Wong RJ. Cancer Sci 112 803-814 (2021)
  146. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, Rosen JM. Cancer Res Commun 1 178-193 (2021)
  147. A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. Tsuji K, Hymel D, Burke TR. Anal Methods 12 4418-4421 (2020)
  148. Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway. Zhao S, Geng Y, Cao L, Yang Q, Pan T, Zhou D, Liu J, Shi Z, Zhang J. Am J Cancer Res 11 2142-2158 (2021)
  149. Design, synthesis and antiproliferative activity of novel substituted 2-amino-7,8-dihydropteridin-6(5H)-one derivatives. Li Q, Yang HK, Sun Q, You WW, Zhao PL. Bioorg Med Chem Lett 27 3954-3958 (2017)
  150. Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma. Fan W, Ma H, Jin B. Oncol Lett 23 146 (2022)
  151. Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs. Park JE, Lee H, Oliva P, Kirsch K, Kim B, Ahn JI, Alverez CN, Gaikwad S, Krausz KW, O'Connor R, Rai G, Simeonov A, Mock BA, Gonzalez FJ, Lee KS, Jacobson KA. ACS Pharmacol Transl Sci 6 422-446 (2023)
  152. Vanillin-derived antiproliferative compounds influence Plk1 activity. Carrasco-Gomez R, Keppner-Witter S, Hieke M, Lange L, Schneider G, Schubert-Zsilavecz M, Proschak E, Spänkuch B. Bioorg Med Chem Lett 24 5063-5069 (2014)
  153. Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies. Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U. BMC Cancer 22 569 (2022)
  154. Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines. Ruiz-Alcaraz AJ, Carmona-Martínez V, Guirado A, Gálvez J, Martínez-Esparza M, García-Peñarrubia P. Naunyn Schmiedebergs Arch Pharmacol 392 219-227 (2019)
  155. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells. Valinciute G, Ecker J, Selt F, Hielscher T, Sigaud R, Ridinger J, Thatikonda V, Gatzweiler C, Robinson S, Talbot J, Bernardi F, Picard D, Blattner-Johnson M, Schmid S, Jones DT, van Tilburg CM, Capper D, Kool M, Remke M, Oehme I, Pfister SM, Roussel MF, Ayrault O, Witt O, Milde T. J Neurooncol 163 143-158 (2023)
  156. Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells. Yang X, Smith JL, Beck MT, Wilkinson JM, Michaud A, Vasta JD, Robers MB, Willson TM. Molecules 28 2950 (2023)
  157. Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations. Normandin K, Coulombe-Huntington J, St-Denis C, Bernard A, Bourouh M, Bertomeu T, Tyers M, Archambault V. PLoS Genet 19 e1010903 (2023)
  158. Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells. Choi EJ, Koo BK, Hur EH, Moon JH, Kim JY, Park HS, Choi Y, Lee KH, Lee JH, Choi EK, Lee JH. Biomol Ther (Seoul) 31 319-329 (2023)
  159. Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma. Wang R, Wang D, Bai X, Guo J, Xia S, Cheng Y, Gu Y, Wang Q, Nie J, Chen D, Liu W, Liang J. Cell Death Discov 9 231 (2023)
  160. Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. Affatato R, Chiappa M, Guffanti F, Ricci F, Formenti L, Fruscio R, Jaconi M, Ridinger M, Erlander M, Damia G. Ther Adv Med Oncol 14 17588359221095064 (2022)
  161. PLK1 inhibition dampens NLRP3 inflammasome-elicited response in inflammatory disease models. Baldrighi M, Doreth C, Li Y, Zhao X, Warner E, Chenoweth H, Kishore K, Umrania Y, Minde DP, Thome S, Yu X, Lu Y, Knapton A, Harrison J, Clarke M, Latz E, de Cárcer G, Malumbres M, Ryffel B, Bryant C, Liu J, Lilley KS, Mallat Z, Li X. J Clin Invest 133 e162129 (2023)
  162. Plk1 promotes renal tubulointerstitial fibrosis by targeting autophagy/lysosome axis. Du Y, Shang Y, Qian Y, Guo Y, Chen S, Lin X, Cao W, Tang X, Zhou A, Huang S, Zhang A, Jia Z, Zhang Y. Cell Death Dis 14 571 (2023)
  163. Polymer-Supported Synthesis of Various Pteridinones and Pyrimidodiazepinones. Chasák J, Brulíková L. Molecules 26 1603 (2021)


Quick links